Cystic Fibrosis Foundation - Group Return for the Chapters

“Hours for related organizations the following is an estimate of the average hours per week devoted to related organizations by the officers: cystic fibrosis cystic fibrosis foundation foundation title headquarters therapeutics, inc. ----- ------------ ------------------ president & ceo 36 20 exec. Vice president & coo 50 5 exec. Vice president & cfo 50 5”

“PART III, LINE 3 Cystic Fibrosis Foundation has determined that its chapters serve more as its local offices than as separate unincorporated associations with separate governance structures and activities. Accordingly, Cystic Fibrosis Foundation has determined that the chapters should not be treated as separate going forward. This is the final return for the chapters. The group exemption will be terminated for the chapters. The local office activity will be reported on Cystic Fibrosis Foundations Form 990 going forward. FILING OF INFORMATION RETURNS PART V, LINES 1 AND 2 THE CENTRAL ORGANIZATION, CYSTIC FIBROSIS FOUNDATION HEADQUARTERS' EIN (13-1930701) FILES THE REQUIRED FORMS 1099, W-2, W-2G, AND 941 RELATED TO THE AMOUNTS REPORTED ON PART V, LINES 1 AND 2. REVIEW OF 990 BY GOVERNING BODY PART VI, SECTION B, LINE 11B THE CYSTIC FIBROSIS FOUNDATION BOARD OF TRUSTEES RECEIVES A DRAFT OF THE FORM 990 PRIOR TO ITS BEING FILED, WITH SUFFICIENT TIME FOR REVIEW AND COMMENT ALLOWED. THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES AND THE FOUNDATIONS ERISA ATTORNEYS REVIEW THE EXECUTIVE COMPENSATION SECTIONS OF THE FORM 990. THE AUDIT COMMITTEE OF THE BOARD OF TRUSTEES ALSO REVIEWS THE FORM 990 AS PART OF ITS CHARTERED RESPONSIBILITIES. IN ALL CASES THE CYSTIC FIBROSIS FOUNDATION BOARD OF TRUSTEES RECEIVED A COMPLETE COPY OF THE FINAL FORM 990 BEFORE IT IS FILED.”

“Part vi, section b, line 12c a conflict of interest disclosure statement is completed annually by each board member and officer. Disclosures provided are reported to the nominating and governance committee, the audit committee and the board of trustees. As required within the bylaws, any potential conflicts of interest must be reported to the board as they arise. When any matter is deemed a potential conflict of interest and requires action by the board of trustees, the interested trustee or officer is required to retire from the room in which the board or its committee is meeting, may not participate in the final deliberation of the matter, and may not vote on the matter. The organization enforced the policy during 2015 and had no conflicts of interest as defined by the policy.”

“Part vi, line 15 the total compensation of executives at the cystic fibrosis foundation is specifically designed to attract and retain the highest qualified executive and medical talent, to fulfill the critically important mission of curing cystic fibrosis and providing all people with the disease the opportunity to lead full, productive lives. The subordinates included in this group return do not have their own officers. Rather, the officers of the cystic fibrosis foundation serve as the officers of each subordinate included in this group return. The independent compensation committee of the cf foundation's board of trustees follows the process described in the irs intermediate sanctions rules when determining compensation for officers. Specifically, the committee: (1) is composed entirely of non-employee volunteer directors who have no familial, business or significant personal relationships with the cf foundation or its executives. (2) assesses the short-term and long-term contribution and performance of each executive in meeting very definitive and quantifiable objectives focused on the cf foundation's mission success. (3) engages an independent compensation consulting firm to compile appropriate comparability data (including compensation market information for peers with whom the cf foundation competes for executive talent) for committee reliance. The committee meets with representatives of the consulting firm to review this data in detail. (4) reviews all elements of each executive's total compensation, including but not limited to base salary, bonuses, perquisites, fringe benefits, and incentive and deferred compensation arrangements. Upon the executives hire, and at each point in time thereafter at which a new or revised compensation arrangement is under consideration with respect to the executive, the committee meets with its independent compensation consulting firm before the arrangement is implemented to evaluate the reasonableness of the arrangement by comparing both the arrangement itself and the executives entire compensation package to compensation packages paid by similarly situated organizations for functionally comparable positions. (5) documents, concurrently with its determination, the basis for its determination in the minutes of its meeting. These minutes are reviewed, revised if necessary and approved at the following meeting of the committee. (6) obtains a written legal opinion concerning the committees compliance with the irs intermediate sanctions rules. The process described above was used to establish compensation for the following officers of the organization: president & ceo executive vice president & coo executive vice president, cfo and secretary the process was last undertaken in 2014, with the exception of that for the ceo position which was last conducted in 2015.”

“PART VI, SECTION C, LINE 19 Forms 1023 and 990-T for the Cystic Fibrosis Foundation were available on its website, CFF.org and the Cystic Fibrosis Foundation's website provided a direct link to its Form 990 on Guidestar.org. The chapters governing documents (chapter operating guidelines and accounting manual) are not required to be made public. The Board and Officer Conflict of Interest Policy and the audited financial statements were available on the Foundations website, www.cff.org, during 2015.”